How to Expand a Telehealth Clinic Beyond GLP-1

If your telehealth clinic runs mostly on compounded GLP-1, the durable growth move is to diversify into adjacent, mostly non-controlled 503A categories that share your existing patients or providers: hormone therapy for men and women, hair loss, sexual health, and skin care. Sequence by overlap, keep a licensed provider approving every order, and route each category to the right pharmacy on infrastructure you already own instead of re-platforming.

Why does over-indexing on GLP-1 create concentration risk?

Because a single regulatory decision can remove most of your revenue overnight. The FDA declared the semaglutide and tirzepatide shortages resolved, and the special allowances that let pharmacies compound copies during the shortage wound down through 2025. A one-category business now sits downstream of one agency position, which is a fragile place to be.

During the shortages, sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act let compounders fill a real supply gap. Once a drug comes off the shortage list, the ground shifts. Under 21 U.S.C. 353a, compounding a drug that is essentially a copy of a commercially available, approved product is generally not permitted, with narrow exceptions (FDA, Compounding and the FDA).

To be precise: this is a restriction with carve-outs, not a blanket ban. A compounder may still prepare a preparation when there is a documented clinical need for something the approved product cannot meet, such as a different formulation, a needed dosage, or a documented allergy to an inactive ingredient. But a clinic cannot build a durable, high-volume business on exceptions that must be justified patient by patient. The strategic read is simple: treat GLP-1 as one line among several, not the foundation. For the specifics of what is and is not allowed right now, see the operator's guide to the current GLP-1 compounding restrictions.

What the numbers look like

Many weight-management-first clinics built 70 to 90 percent (estimated) of revenue on compounded semaglutide or tirzepatide during the shortage window. When that concentration meets a regulatory change, the exposure is obvious. Diversification is not a nice-to-have; it is the difference between a clinic that absorbs a shock and one that does not.

How should a telehealth clinic choose which categories to add?

Choose by adjacency, not by hype. The best next category shares either the same patient you already have or the same provider network you already work with. Adjacency lowers acquisition cost, shortens clinical onboarding, and keeps your compliance posture inside familiar, mostly non-controlled 503A territory.

There are two adjacency axes worth mapping:

• Same patient. A man on a weight protocol is a plausible candidate for TRT screening, hair loss treatment, or sexual health support. You already have the relationship and the intake history, so the marginal acquisition cost is low.
• Same provider. If your clinician network is comfortable with metabolic and hormone protocols, HRT and menopause care extend naturally from work they already do, without standing up a new specialty.

Work non-controlled 503A first because it keeps your regulatory surface small and predictable. Controlled substances and unsettled categories add licensing, monitoring, and documentation burdens that can slow a young clinic down. A deeper margin-by-category comparison lives in which categories carry the best margins beyond GLP-1.

Candidate categories at a glance

The table below sketches the shape of common expansion categories. Treat every figure as directional and clinic-specific; the demand, CAC, and margin cells are marked estimated because they vary widely by market, funnel, and pharmacy relationship.

Category	Demand (estimated)	CAC (estimated)	Margin shape (estimated)	Regulatory risk
TRT / men's health	High	Medium	Healthy, recurring	Low–moderate (mostly non-controlled 503A; some testosterone scheduling considerations by state)
HRT / menopause	High	Medium	Healthy, recurring	Low (non-controlled 503A)
Hair loss	High	Low–medium	Solid, high retention	Low (non-controlled 503A)
Sexual health / ED	High	Low–medium	Solid	Low–moderate (mostly non-controlled)
Skin / aesthetics (e.g. tretinoin)	Medium–high	Low	Solid, sticky	Low (non-controlled 503A)
Peptides / NAD+ / low-dose naltrexone	Variable	Medium	Variable	Elevated and variable — peptide status differs by product; some not permitted for compounding

The pattern is clear: the lower-risk, patient-adjacent lines are where a diversifying clinic should start. Peptides, NAD+, and low-dose naltrexone can have a place under careful provider oversight, but their regulatory picture is less settled and, for some peptides, unfavorable. They belong later in the sequence and always with documentation. For a fuller treatment of that category, see telehealth category expansion into peptides and hormones.

How do you sequence the rollout without stalling operations?

Sequence in waves, anchored to patient overlap and provider comfort. Add one category at a time, prove the intake-to-fulfillment loop end to end, then layer the next. Trying to launch five categories at once spreads clinical attention thin and multiplies the number of new pharmacy relationships you have to prove out simultaneously.

A workable sequence for a weight-management-first clinic:

1. Wave one — nearest neighbors. Add the category with the highest overlap with your current book. For many clinics that is men's health or hormone therapy, because the patient and the provider are already in the building.
2. Wave two — high-retention utility lines. Hair loss and skin care are low-CAC, sticky, and clinically straightforward. They smooth revenue and raise lifetime value without much new operational load.
3. Wave three — considered add-ons. Sexual health rounds out the men's and women's health offering. Only after these are stable should you evaluate peptides or other categories with heavier documentation needs.

Each wave should clear the same bar before you move on: a working questionnaire, a provider who will stand behind approvals, a pharmacy that can fulfill reliably, and clean order routing. The related walkthrough on scaling a telehealth clinic across multiple categories goes deeper on the operational cadence.

Keep the provider at the center

Expansion never changes the core rule: a licensed provider approves every order in every category. New categories mean new clinical questions, so each one gets its own intake logic and its own approval path. Diversification broadens the formulary; it does not loosen the gate.

Why does owning your stack make expansion cheap?

Because when you own the rail, your storefront, and your patient data as the system of record, adding a category is a configuration change rather than a procurement project. You add the pharmacy, define the intake, and route the new orders. The economics of expansion depend almost entirely on which side of that line you are on.

On a rented, closed platform, every new category tends to become a vendor negotiation: new terms, a new integration, sometimes a new data silo, and a new dependency you do not control. Do that five times and expansion is slow and expensive by construction. Own the infrastructure and the pharmacy becomes a routing target, not a gatekeeper. That is the difference category diversification as margin protection is built on.

Two capabilities do most of the work:

• Cross-pharmacy order routing. Different categories are best served by different pharmacies. If your rail can route each order to the right one, you can add a category by adding a pharmacy, not by re-platforming. See how multi-pharmacy order routing works.
• Owning your patient data. When the clinic is the system of record, patient history, consents, and order data travel with you across categories and pharmacies. That is what makes same-patient expansion actually cheap, and it is why owning your patient data as the system of record is foundational rather than a feature.

The overlay model in practice

neolife is the fulfillment rail that sits on top of the compounding pharmacy a clinic already uses. AI-native intake, compliance, and cross-pharmacy routing run as an overlay, so operators keep their own storefront, own their patient data, and add pharmacies and categories without a rip-and-replace. Pricing is flat fair-market-value SaaS plus a per-order buy-down, and pharmacies are free — the model rewards you for adding categories, not for concentrating value in any one of them.

What is the takeaway for operators right now?

The GLP-1 shortage resolution is a signal, not a one-off. Any single compounded category can be reshaped by an FDA position, a supply change, or a pharmacy issue. The clinics that endure are the ones spread across several durable, provider-gated lines, running on infrastructure they control.

Start with the category nearest your current patients, keep a licensed provider approving every order, work non-controlled 503A first, and treat the less-settled categories like peptides with appropriate caution and documentation. If you own the rail, each of those moves is a routing decision instead of a rebuild.

Want to expand without re-platforming? Own the rail and add categories as routing, not as vendor negotiations. Talk to us.

This article is for informational purposes only and is not legal, medical, or regulatory advice; consult qualified counsel and licensed clinicians for your specific situation.